Study of Codivir in Patients With COVID-19
Study Details
Study Description
Brief Summary
This is an open-label study to evaluate the safety and preliminary efficacy of Codivir in 12 mild or moderate COVID-19 patients and onset of symptoms within 72h prior to their inclusion. Treatment will begin in the hospital, participants will be discharged at Day 4 and continue the treatment up to Day 10 at home and followed up to day 28.
| Condition or Disease | Intervention/Treatment | Phase |
|---|---|---|
|
Phase 1 |
Detailed Description
Eligible participants who agree to participate will be submitted to safety assessments, an RT-PCR and a quick test for COVID-19. Everyone will receive the treatments indicated for their case, except for other investigational medications. Codivir will be administered in addition to these treatments at a dose of 20 mg SC twice daily for 10 days. Participants will remain hospitalized for the first 3 days.
If they have progressed well, they will continue the treatment up to Day 10 at home, receiving a nurse's home visit twice a day to administer Codivir and collect vital signs. Participants will be followed up to Day 28 by telemedicine. A doctor will call them periodically to monitor the clinical evolution, collect adverse events, concomitant medication and instruct the participants. In case of unfavorable evolution, the participants will remain hospitalized receiving the appropriate care. The investigator will decide whether or not the investigational medication will continue, considering the participant's health and well-being.
Study Design
Arms and Interventions
| Arm | Intervention/Treatment |
|---|---|
| Experimental: Covidir Patient (adults aged ≥18 years) with mild or moderate COVID-19 and flu-symptoms onset within 72 hours prior to inclusion. Treatment begins at the hospital. On the 4th day, participants who are well will be discharged and continue treatment up to Day 10 at home. All participants will receive Codivir 20 mg SC 2 x daily. |
Drug: Covidir injections
administration of the investigational product CODIVIR at a dose of 20 mg twice a day subcutaneously.
Other Names:
Diagnostic Test: One Step Test
rapid test for the diagnosis of COVID-19 based on the detection of anti-SARS-CoV-2 in the blood.
Other Names:
Diagnostic Test: IgM and IgG dosage
blood collection for dosage of Anti SARS-CoV-2 antibodies.
Other Names:
Diagnostic Test: RT-PCR SARS-CoV-2
detection of viral RNA in nasopharyngeal and oropharyngeal samples by the Real Time Protein Chain Reaction technique.
Other Names:
Diagnostic Test: Screening blood test
complete blood count, urea, creatinine, uric acid, sodium, potassium, chloride, calcium, glucose, glycated hemoglobin, alkaline phosphatase (FA), alanine aminotransferase (ALT), aspartate aminotransferase (AST), total bilirubins and fractions ( BTF), total proteins and fractions (PTF), lipid profile (total cholesterol, fractions and triglycerides); coagulogram (TP, aPTT); D-dimer; C-reactive protein; HIV, HBV, HCV serology; Ferritin; fibrinogen, Pregnancy test for non-sterile women.
Other Names:
Diagnostic Test: ECG
12-lead electrocardiogram with report.
Other Names:
Diagnostic Test: Medical evaluation
evaluation by the principal investigator or assistant physician with a complete physical examination.
Other Names:
Diagnostic Test: NEWS-2 score
assessment of the participant by the NEWS-2 score.
Diagnostic Test: WHO score
assessment of the participant by the score of the World Health Organization.
|
Outcome Measures
Primary Outcome Measures
- Incidence and severity of adverse events related to the investigational product. [28 days]
Secondary Outcome Measures
- Clinical evolution according to the score of the World Health Organization between admission and days 10 and 28. [up to 28 days]
- Clinical evolution according to NEWS2 score between admission and days 10 and 28. [up to 28 days]
- RT-PCR negative. [up to 28 days]
- Evolution of IgM & IgG Anti-SARS-CoV-2. [up to 28 days]
Eligibility Criteria
Criteria
Inclusion Criteria:
-
Age between 18 and 60 years;
-
Male or female;
-
SARS-CoV-2 infection indicated by rapid test and confirmed by RT-PCR.
-
Mild or moderate COVID-19:
-
The oxygen saturation in room air >93%;
-
<30 breaths per minute;
-
No signs of hemodynamic decompensation.
-
Absence of pregnancy in women of childbearing age.
-
Able to understand and comply with the requirements of the protocol.
-
Consent to participate
Exclusion Criteria:
-
Participants in need of O2 supplementation by catheter or mask, invasive mechanical ventilation, or vasopressors.
-
Onset of symptoms or rapid test or positive RT-PCR for more than 72 hours of inclusion.
-
Participants in use or expected to use within 24 hours prior to the inclusion of drugs that are under clinical investigation as a therapeutic option for the treatment of COVID-19 (eg hydroxychloroquine, chloroquine, ivermectin, nitazoxanide, among others) during the study period;
-
Body mass index less than 19.9 or greater than 35;
-
Comorbidities such as: other serious infections, active malignancies, autoimmune diseases, liver, kidney or heart failure; another systemic disease and / or laboratory abnormality, which, in the investigator's opinion, prevent the patient from participating in the study;
-
Concomitant HIV, HBV or HCV infection.
-
Pregnancy or lactation;
-
Participation in another clinical trial in the 12 months preceding inclusion;
-
Anti-COVID-19 vaccination at any time;
-
Vaccination for any other infection in the 4 weeks prior to inclusion;
-
Any condition that increases the risk of participating in the study, in the opinion of the investigator.
Contacts and Locations
Locations
| Site | City | State | Country | Postal Code | |
|---|---|---|---|---|---|
| 1 | Hospital Vera Cruz S A (Campinas-SP) | Campinas | State Of São Paulo | Brazil | 13092-108 |
Sponsors and Collaborators
- Code Pharma
Investigators
- Study Director: Eynat Finkelshtein, Code Pharma
Study Documents (Full-Text)
None provided.More Information
Publications
None provided.- 20-01-ZM